The Benefits of Clinical Trials

Clinical trials represent top-edge medical science. Even so, less than five% of adults diagnosed with cancer each year are enrolled in them. Although there are a number of various therapy approaches being supplied, 8/10 patients are not aware that this is a viable choice for them. If they are supplying treatment choices above and beyond the normal remedy, why are patients not utilizing this beneficial resource?

Outcomes from surveys and focus groups concluded that the vast majority of patients are unaware of clinical trials and doctors are not enrolling patients due to a lack of time, staffing, funding, and resources. Indeed, enrolling a patient in a trial needs a important amount of time and resources for physicians. Additionally, there are some significant misconceptions held by some physicians and patients.

Molecular targeted clinical trials require to be viewed separately from other trials.

Given that targeted trials are based on properly-established molecular mechanisms, they do not need huge-scale research to produce relevant statistical data. This is an critical distinction as the tactics utilised to determine the far more general chemotherapy drugs at present being utilised, had been based on applying the exact same drug to several patients with a specific form of cancer, and did not contemplate the genetic variation amongst the patients, their cancers, or diet program. In the case of these generalized and less stratified trials, big numbers of patients had been required to produce relevant statistical information.

A frequent myth is that a patient might get a placebo (control group) rather of the remedy being tested (single or double blind research). Nevertheless, clinical trials for cancer do not generally use this method. There are two considerations concerning this point. Firstly, if a placebo or manage group is utilised in a trial, it is almost constantly the normal therapy for that cancer that the patient would have otherwise used.

Secondly, most targeted clinical trials are open label and the patient has the choice of what role they perform. Additionally, if the tested drug starts to show substantial benefits, the control group is given the alternative to switch to the drug as it would be extremely unethical to deny a patient with a precise genetic marker, useful remedy.

The use of molecular signatures in identifying optimal therapies has difficulties and positive aspects.

(1) Molecular targeted clinical trials require expensive and complex genetic profiling.

(2) Molecular targeted clinical trials give a tool to address the heterogeneous nature of cancer and have far much less side effects than common chemotherapy/RT.

Whilst the numerous variations of therapeutic approaches combined with the complexity of navigating the copious clinical trials databases has proved a daunting job, this work can be drastically mitigated by having a statistically determined molecular outline that makes it possible for the user to concentrate on locating trials based on pre-defined molecular variables (markers). Not only does this approach decrease the time and effort required, it enables for personalized remedies (much better outcomes with much less side effects), reduces the patient burden for the physician and medical method, and supplies scientific information. Moreover, even if the patient is not accepted in the trial, they are offered with critical molecular data that can tremendously enhance further therapy efforts.

And finally, employing many targeted clinical trials enables the patient to greatly minimize the general genetic variation of their cancer, 1 trial at a time.